Researchers from the University of Gothenburg and the University of Copenhagen reviewed evidence on whether semaglutide and tirzepatide, popular weight loss and diabetes medications, might affect brain function. The review was invited by the journal Science.
Animal studies suggest GLP-1 medications can influence learning and memory. Human research has produced mixed results. Health record analyses found an association between GLP-1 treatment and reduced dementia risk in people with type 2 diabetes, but these observational findings cannot prove the medications caused the reduction.
Clinical trials produced less encouraging results. Novo Nordisk's EVOKE and EVOKE+ trials found that semaglutide failed to slow progression of early Alzheimer's disease, despite affecting biological markers associated with the condition.
However, researchers believe these medications could still benefit cognition in other ways. People with obesity or type 2 diabetes sometimes experience problems with attention, planning, and information processing that relate to metabolic health and blood vessel function. These cognitive issues may respond differently to treatment than established neurodegenerative disease.
Stina Borchers, the review's first author, stated that researchers need to determine "whether these treatments can help people with obesity or diabetes preserve their cognitive abilities, particularly if treatment begins before cognitive problems become established."
Christoffer Clemmensen, the review's senior author and a research group leader at the University of Copenhagen, said the medications offer opportunities to understand how metabolism influences brain function. He noted that researchers may eventually develop treatments designed specifically to preserve cognitive function.
The researchers called for clinical trials evaluating memory and attention beginning when patients start treatment. They also warned that rapid weight loss can reduce muscle mass, particularly in older adults and physically frail people, potentially offsetting cognitive benefits.